Dangerous Ideas In Drug Development

Talk 1: Maria Mury, Cancer Institute New South Wales: CINSW, supporting clinical trials and cancer careTalk 2: Dr Matthew Krebs, Manchester Cancer Research Centre: Practical aspects on new generation precision medicine in 2025

Talk 1: A/Prof Pratiti (Mimi) Bandopadhayay, Dana Farber Cancer Institute: Emerging precision oncology in brain tumoursTalk 2: Dr Frank Lin, UNSW: Integrating IT tools into trials of precision oncology

Talk 1: Prof Louise Emmett, St Vincent's Hospital Sydney: Latest advances in theranostics for oncologyTalk 2: Prof Shaneen Sandhu, Peter MacCallum Cancer Centre: Embedding translational science in radio medical oncology

Highlight Talk 1 -  Dr Jordan Cohen, Calvary Mater Newcastle: Decentralised clinical trials innovation and practiceHighlight Talk 2 -  Dr Connie Diakos, Royal North Shore Hospital Sydney: North Star VNP: a model for international collaborationHighlight Talk 3 -  Prof Jayesh Desai, Peter MacCallum Cancer Centre: Clinical trials within the Victorian ecosystem

Speaker: Prof William Sellers, Broad Institute Harvard

Tune in this time to find out more about NSW's lead cancer control agency - Cancer Insitute NSW. We are joined by Prof Tracey O'Brien, Chief Cancer Officer to talk about her career to date and insights into CINSW's work across the state.

How do we make sure we run the best trials in appropriate locations? Do individual trial centres and investigators work together around the world? A recent paper published in Journal of Clinical Oncology reviews how early phase consortia globally are working to improve cancer clinical trials and drug development - its great to see NECTA alongside many other consortia worldwide https://ascopubs.org/doi/10.1200/JCO-24-01534 We're joined in this episode by three of the authors from the recent paper to discuss their views on how academic networks can accelerate global drug development.

How can we grow paediatric clinical trials globally? This episode, we talk with Dr Sam Blackman to discuss the challenges and importance of efforts to develop new agents in paediatric oncology. We'll tackle how the complexity of these trial types can be balanced with realities of commercial drug development, and what new models could be adopted in the future.

Join us this week for a fascinating chat with Dr Paul Kelly, a leading Australian 'physician-investor'. We'll hear first hand insights into how venture funds work with the biotech industry to enable great science to move to the clinic. There'll also be some helpful advice for anyone interested in exploring a career in the early stage translational space!

In our latest episode we're joined by Etira, a company exploring a novel mechanism of inducing targeted ER stress in cancer. Learn with us about how LIPA is targeted to generate anticancer effects with prospects across many cancers.

In this episode we hear an amazing personal and professional story with GBM from Brad Sorenson, the founder of a cutting-edge biotech. We'll learn about the applications of lipid mRNA tech and its use as a platform for diverse research. #mRNA #GBM #biotech #drugdevelopment

This time we talk with the esteemed Prof Lillian Siu from Princess Margaret Cancer Centre, Toronto and our own Dr Joe Wei. Learn with us how phase 1 trials have evolved today to become much more sophisticated as new mechanisms and approaches emerge to challenge us. We dive into questions such as whether targeted agents in mono + combination therapy should be a standard approach. How can we make cold tumours become hot, or even lukewarm? #drugdevelopment #globaltalks #labtoclinic

This episode we're joined by Sydney-based Dr Christine Chaffer and Dr Rachel Dear who share with us a fascinating story in local Australian drug development. Learn about how this collaboration between our very own Garvan Institute and St Vincent's Hospital effectively combined scientific research and clinical study to investigate an exciting new treatment option for breast cancer patients. #AUS #drugdevelopment #clinicaltranslation

How can we improve equitable access to early clinical trials across a country as large as Australia? This week, we talk with Prof Craig Underhill about how teletrials is revolutionising the trials sector and enabling regional and remote participants. We dive into how far we've come, the challenges in deploying this approach across Australia, and the multifaceted benefits for everyone in the space. #teletrials #RAR #earlyphase #futureofhealth

Today we're diving into dendrimer technology with an Australian biotech - Starpharma. We discuss promising results from recent trials that have adapted conventional therapies in new ways to improve efficacy and tolerability, and delve into exciting future applications.

Today we'll be speaking with Grey Wolf Therapeutics to hear about their astounding work with ERAP inhibition to target antigen presentation in tumour cells. This novel direction is broadly applicable across many tumour types, and we'll learn about exciting exploration of the peptide library to develop specific therapies along with potential next steps for pairing with T-cell treatment.

Learn how the pandemic has helped transform RNA as a platform for oncology drug development in this week's episode. We'll be chatting with Myeloid Therapeutics, who are using RNA technology to direct myeloid cells to harness the innate and adaptive immune system for anti-tumour activity.

This week we chat with a guest from Immunocore who specialise in soluble T-cell receptor technology. We'll be diving into their work with KIMMTRAK in uveal melanoma, as well as exciting upcoming studies with PRAME and PIWIL1 across multiple cancer types.

Join us as we speak with Ideaya Biosciences to learn about their latest exciting molecules under development. We'll be covering: promising progress in uveal melanoma with darovasertib (PKCi) + crizotinib; new results in MTAP deficient settings with MAT2Ai + PRMT5i; and next generation molecules for PARPi resistant tumours.